University of Arizona Cancer Center researchers recently found a promising method to battle cancer, slow its growth and overcome drug resistance. Noel Warfel, PhD, an associate professor of Cellular and Molecular Medicine at the College of Medicine – Tucson, is leading the study.

Michael Badowski, PhD, an associate research scientist at the University of Arizona Health Sciences Biorepository, writes that the response to the COVID-19 outbreak has better prepared global infrastructure for a more deadly pandemic.

Researchers find lower immune response to COVID-19 vaccine for patients on chemotherapy; third dose of Pfizer-BioNTech vaccine boosts immune response.

The grant will help address COVID-19 disparities among racial and ethnic minority populations and rural communities in Arizona.

The National Institutes of Health -unded network aims to develop more effective brain-aging treatments and interventions targeted to the individual.

New research at the University of Arizona Health Sciences found that patients undergoing active chemotherapy had a lower immune response to two doses of the COVID-19 vaccine, but a third dose increased response. "We wanted to make sure we understand the level of protection the COVID-19 vaccines are offering our cancer patients, especially as restrictions were being eased and more contagious variants were starting to spread," said Rachna Shroff, MD, MS, chief of Gastrointestinal Medical Oncology at the UArizona Cancer Center and director of the Cancer Center Clinical Trials Office.

Murtaza Akhter, MD, an emergency medicine physician at the College of Medicine – Phoenix, discusses the stress on doctors and nurses in hospitals in states hardest hit by the covid delta surge.

University of Arizona College of Nursing BSN program ranked No. 1 in Arizona, No. 23 nationally and No. 16 among public universities.

23 medical students awarded scholarships promise to work in underserved communities in Arizona after graduation and residency.

Several European nations have decided to "live with COVID-19" rather than focus largely on trying to eradicate the virus, but experts say that strategy likely would fail in the U.S. because case levels vary widely across the country and cases overall are too high right now to try. Kacey Ernst, PhD, MPH, epidemiologist at the Mel and Enid Zuckerman College of Public Health, is quoted.